Anti-Mouse CD45.2 [Clone 104.2] — Purified in vivo GOLD™ Functional Grade

Clone 104.2 is an anti-mouse CD45.2 monoclonal antibody commonly used in vivo in mice to distinguish, track, or manipulate hematopoietic cells from CD45.2+ strains and to functionally block specific immune pathways, including in autoimmune disease models.

Essential in vivo applications of clone 104.2 in mice include:

• Identification and tracking of hematopoietic cells: Clone 104.2 specifically binds CD45.2 (Ly5.2), a leukocyte antigen found in many laboratory mouse strains (e.g., C57BL/6, BALB/c), but not in CD45.1 strains. This makes it a key reagent for experiments involving bone marrow chimeras, immune cell transfer, or tracking donor vs. recipient cells after transplantation.
• Flow cytometry and immunofluorescence microscopy: Used to specifically label and analyze CD45.2+ cells in vivo and ex vivo, enabling quantitation and functional assays of immune cell subsets in major immunological studies.
• Functional blockade of CD45.2: Clone 104.2 has been shown to block B cell responses and reduce serum autoantibody concentrations in vivo, particularly in SLE-prone (systemic lupus erythematosus) mouse models, implicating its use in immune regulation and autoimmune research.
• Immunohistochemistry: Applied to tissue sections for visualizing CD45.2+ leukocyte infiltration and localization in organs or inflamed tissues in vivo.

Additional relevant details:

• Clone 104.2 does not react with CD45.1+ cells (expressed in mouse strains like SJL/J, DA, and RIII), ensuring precise discrimination between genetic backgrounds in experimental settings.
• Its ability to block B cell signaling and modulate autoantibody levels supports application in therapeutic testing and mechanistic studies of immunopathology.
• Typically used in mouse strains expressing CD45.2 for adoptive transfer experiments, tracking immune reconstitution following irradiation, or in autoimmune disease models to monitor or manipulate immune cell function.

In summary, clone 104.2 is a versatile tool for in vivo immunological research in mice, essential for tracking CD45.2+ cells and modulating immune responses, particularly in experimental immunology, hematopoietic cell transplantation, and autoimmune disease studies.

The antibody clone 104.2 is widely used to detect the mouse alloantigen CD45.2 (Ly5.2), a common leukocyte marker for distinguishing mouse strains in immunology research, particularly in flow cytometry applications. In the literature, 104.2 is most often used together with antibodies or proteins that identify specific hematopoietic or immune cell subsets, allowing for the detailed phenotyping of immune populations within mouse models.

Commonly used antibodies or proteins paired with 104.2 include:

• CD45.1 antibody: Used to distinguish donor and host origin in transplantation experiments or mixed bone marrow chimeras, since CD45.1 and CD45.2 are allelic variants. Often, 104.2 (CD45.2-specific) is paired with a CD45.1-specific antibody (e.g., clone A20) to profile chimerism or lineage tracing in mice, especially when donor and recipient mice carry different alleles of CD45.
• T cell markers:
  • CD3: General T cell marker.
  • CD4: Helper T cell marker.
  • CD8: Cytotoxic T cell marker.
• B cell marker:
  • CD19: Identifies B cells.
• Myeloid/monocyte/macrophage markers:
  • CD11b, CD11c, Ly6G, F4/80: Used to profile various myeloid cell types.
• Other lineage or activation markers:
  • NK1.1 (for NK cells), CD25, CD44, CD62L, among others, depending on study focus.

In flow cytometry, these antibodies are often used in multiparametric panels to simultaneously assess immune cell origin (CD45.1 vs. CD45.2) and subtype, function, or activation state. This approach is fundamental in immunological studies, adoptive transfers, hematopoietic stem cell research, and immune reconstitution analyses.

Occasionally, isotype controls matched to 104.2 (such as mouse IgG2a, κ clones) are included to assess non-specific binding.

Summary table of commonly paired antibodies/proteins with 104.2:

References:

• 104.2 antibody use and application: Assay Genie, Elabscience, Fine Test.
• Strategy for immunophenotyping and commonly used markers: NCBI Bookshelf, general immunology protocols.

If a more specific pairing in a particular research context is required (e.g., stem cell, transplantation, or disease model), please specify that context for tailored recommendations.

The clone 104.2 antibody is widely cited in scientific literature for its specificity against the mouse CD45.2 alloantigen, enabling discrimination of CD45.2-expressing mouse strains from those expressing CD45.1. Key findings from these citations highlight:

• Specificity of 104.2: This monoclonal antibody reacts only with CD45.2 (Ly5.2), not with CD45.1 (Ly5.1), making it essential for experiments involving congenic mouse strains, such as C57BL/6 and BALB/c versus SJL/J and DA.
• Application in Immunology:
  • Used extensively in hematopoietic cell tracking, adoptive transfers, bone marrow transplantation, and immune cell reconstitution studies to distinguish donor versus host cells.
  • Facilitates distinction in flow cytometry and cell sorting, significantly aiding lineage tracing and immune cell population analysis.
• Biological Insights:
  • CD45.2 is present on all hematopoietic cells except mature erythrocytes and platelets; it is implicated in TCR and BCR signal transduction, meaning studies using 104.2 help elucidate immune cell functional mechanisms.
  • The 104.2 antibody has been shown to block B cell responses in vitro and reduce serum autoantibody concentration in vivo in lupus-prone mice, indicating a role in immune modulation and providing mechanistic insight into autoimmune diseases.
• Technical Utility:
  • Frequently cited for its role in immune chimerism studies and for parsing cellular dynamics in research targeting diseases or transplantation outcomes.
  • Standardization of immunophenotyping in mouse models relies on 104.2 for robust, repeatable segregation of immune cell populations.

In summary, scientific citations of clone 104.2 highlight its central role in mouse immunology and transplantation research for precise lineage marking, immune modulation studies, and cellular tracking.

Dosing regimens for clone 104.2 (anti-mouse CD45.2) primarily vary based on their intended use (e.g., flow cytometry vs. in vivo functional studies) and the genetic background of the mouse model, rather than intrinsic differences between mouse strains that express CD45.2. Precise dosing protocols are often application-specific, as the antibody has two main uses: in vivo modulation (e.g., B cell inhibition or depletion) and flow cytometry or cell sorting.

Key Points:

• Clone 104.2 targets CD45.2, an alloantigen expressed on many common strains (e.g., C57BL/6, 129, BALB/c, C3H/He, etc.) but not on CD45.1-expressing strains (e.g., SJL/J, DA, RIII, STS/A). Dosing regimens will be relevant and effective only in CD45.2+ strains.

• In vivo depletion or functional block: Published functional studies (e.g., B cell inhibition, modulation of autoimmune response) typically utilize doses in the range of 100–500 µg per mouse per injection, administered either intraperitoneally (IP) or intravenously (IV), and repeated every 3–7 days, depending on the desired degree and duration of depletion or modulation.

  • For example, anti-mouse immune checkpoint or depletion antibodies for in vivo use often follow:
    • Dose: 100–500 µg per mouse (as a general guideline across antibodies of similar class).
    • Route: IP or IV.
    • Frequency: Every 3–7 days, or as required by experiment duration and immune cell turnover.

• Flow cytometry or cell sorting (ex vivo labeling):

  • Dose: Typically 0.06–2 µg per test (depending on the manufacturer’s recommendation and cell number; generally 0.2–0.5 µg per (10^6) cells).
  • Route: Cell surface labeling (in vitro, on ice).

• Disease model-specific regimens: In models of autoimmunity (e.g., systemic lupus erythematosus–prone mice), clone 104.2 has been used to reduce autoantibody titers and ameliorate renal pathology, with in vivo dosing often falling within the standard 100–500 µg range. These usually require repeated dosing to sustain effects, but specific variations may be employed to match disease kinetics or immune reconstitution.

• Example from product data: Bio X Cell and others list clone 104.2 as validated for both in vivo and in vitro use with no exact universal regimen, but their technical sheets and literature suggest staying within 100–500 µg per mouse per injection for in vivo work.

Essential context:

• No substantial evidence was found for major differences in dosing between different CD45.2+ mouse strains. The main variation relates to immune cell kinetics, experimental goal (depletion vs. blockade), or disease kinetics—not inherent pharmacokinetic differences between CD45.2+ strains.
• Do not use clone 104.2 in CD45.1 mice—it will not bind or function.

Caveats: If a protocol involves unique requirements (e.g., specific depletion timelines, co-administration with other antibodies), adjustment of dose and schedule may be needed—consult recent primary studies or supplier technical data for tailored recommendations.

Summary: Dosing for clone 104.2 across different mouse models is guided by the application (e.g., depletion vs. labeling) and is largely constant for all CD45.2-expressing strains, with typical in vivo doses of 100–500 µg per mouse every 3–7 days. For flow cytometry, much lower quantities are used per sample.